Efficacy and safety of highly purified urinary follicle-stimulating hormone with human chorionic gonadotropin for treating men with isolated hypogonadotropic hypogonadism. European Metrodin HP Study Group.

The source lists no authors.

Fertility and sterility1 Aug 1998Cited by 48 (Europe PMC)

PMID9696217DOI10.1016/s0015-0282(98)00156-3PepBankPUB-09696217

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, hCG (human chorionic gonadotropin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking hCG (human chorionic gonadotropin).

01HumanNot a test of hCG (human chorionic gonadotropin) aloneNon-randomized trialEfficacy outcome
In men with complete hypogonadotropic hypogonadism, FSH with hCG produced sperm density >1.5 x 10(6)/mL in 18 patients (64.3%).
In plain wordsIn men with hypogonadotropic hypogonadism, FSH with hCG produced the specified sperm density in some patients.
Peptide
hCG (human chorionic gonadotropin)
Outcome
IncreaseSperm density threshold
Study
n = 28
Analysis
Primary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
Patients with sperm density above threshold
18 patients (of 28)
density >1.5 x 10(6)/mL
Patients with sperm density above threshold
64.3%
density >1.5 x 10(6)/mL
Sperm density threshold achieved
> 1.5 x 10(6)/mL
18 patients (64.3%), FSH with hCG
Source sentences
Summary
18 (64.3%) achieved a density of >1.5 x 10(6)/mL.
4 context sentences(design, population, supporting numbers)
Summary · context
The primary efficacy end point was a sperm density of at least 1.5 x 10(6) mL.
Summary · context
Prospective, open, noncomparative, multicenter study.
Summary · context
Twenty-eight men with primary, complete isolated hypogonadotropic hypogonadism.
Summary · context
The administration of hCG for 3-6 months followed by the administration of SC highly purified urinary FSH in combination with hCG for 18 months.
In this study, hCG (human chorionic gonadotropin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking hCG (human chorionic gonadotropin).
Report a problemFND-0969621702
02HumanNot a test of hCG (human chorionic gonadotropin) aloneNon-randomized trialEfficacy outcome
In men with complete hypogonadotropic hypogonadism, all secondary end points improved during FSH with hCG treatment.
In plain wordsIn men with hypogonadotropic hypogonadism, all secondary measures improved during FSH with hCG treatment.
Peptide
hCG (human chorionic gonadotropin)
Outcome
IncreaseSecondary efficacy end points
Study
n = 28
Analysis
Secondary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Source sentences
Summary
All secondary end points were improved.
4 context sentences(design, population, supporting numbers)
Summary · context
Secondary efficacy end points included mean testicular volume, serum inhibin concentration, semen analysis, and pregnancy in the female partner for couples who desired fertility.
Summary · context
Prospective, open, noncomparative, multicenter study.
Summary · context
Twenty-eight men with primary, complete isolated hypogonadotropic hypogonadism.
Summary · context
The administration of hCG for 3-6 months followed by the administration of SC highly purified urinary FSH in combination with hCG for 18 months.
In this study, hCG (human chorionic gonadotropin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking hCG (human chorionic gonadotropin).
Report a problemFND-0969621703
03HumanNot a test of hCG (human chorionic gonadotropin) aloneNon-randomized trialEfficacy outcome
In men with complete hypogonadotropic hypogonadism, FSH with hCG induced spermatogenesis in twenty-five patients (89.3%).
In plain wordsIn men with hypogonadotropic hypogonadism, FSH with hCG induced sperm production.
Peptide
hCG (human chorionic gonadotropin)
Outcome
IncreaseSpermatogenesis
Study
n = 28
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
Patients achieving spermatogenesis
25 patients (of 28)
FSH with hCG
Patients achieving spermatogenesis
89.3%
FSH with hCG
Source sentences
Summary
Twenty-five (89.3%) patients achieved spermatogenesis;
3 context sentences(design, population, supporting numbers)
Summary · context
Prospective, open, noncomparative, multicenter study.
Summary · context
Twenty-eight men with primary, complete isolated hypogonadotropic hypogonadism.
Summary · context
The administration of hCG for 3-6 months followed by the administration of SC highly purified urinary FSH in combination with hCG for 18 months.
In this study, hCG (human chorionic gonadotropin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking hCG (human chorionic gonadotropin).
Report a problemFND-0969621701
04HumanNot a test of hCG (human chorionic gonadotropin) aloneNon-randomized trialSafety outcome
In men with complete hypogonadotropic hypogonadism, no serious study drug-related adverse events occurred during FSH with hCG treatment.
In plain wordsIn men with hypogonadotropic hypogonadism, FSH with hCG treatment had no serious drug-related adverse events.
Peptide
hCG (human chorionic gonadotropin)
Outcome
Not applicableSerious drug-related adverse events
Study
n = 28
Outcome group
Adverse events · Whole body
Source sentences
Summary
No serious study drug-related adverse events were recorded.
3 context sentences(design, population, supporting numbers)
Summary · context
Prospective, open, noncomparative, multicenter study.
Summary · context
Twenty-eight men with primary, complete isolated hypogonadotropic hypogonadism.
Summary · context
The administration of hCG for 3-6 months followed by the administration of SC highly purified urinary FSH in combination with hCG for 18 months.
In this study, hCG (human chorionic gonadotropin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking hCG (human chorionic gonadotropin).
Report a problemFND-0969621704

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.